This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

PlaqueTec secures $5m investment to advance novel cardiovascular disease data platform

Picture of Danny Lee
By Danny Lee
22 May 2026 10 min read
Modern office building with garden

Our Corporate and M&A team has advised PlaqueTec Limited, a Cambridge‑based medtech company pioneering intracoronary liquid biopsy technologies, on its $5 million investment fundraise, which was oversubscribed and backed entirely by the company’s existing shareholders.

The financing will support the continued development of PlaqueTec’s proprietary cardiovascular disease data platform, BioCarta™, a growing repository of unique intracoronary proteomic and clinical data. The BioCarta platform is designed to inform more precise patient stratification and support the development of targeted therapeutic programmes for cardiovascular disease.

PlaqueTec’s technology enables the assessment of proteomic biomarkers at the site of coronary plaque formation, generating insights that cannot be obtained through conventional systemic blood tests. Data generated through the company’s ongoing BIOPATTERN clinical trial is already identifying novel inflammatory drivers across key patient sub‑groups, positioning BioCarta as a highly differentiated asset for partnership, licensing and therapeutic development.

The team was led by senior associate Katie Carter, partner Alex Lloyd and solicitor Sophie Dicks.

“PlaqueTec is building a genuinely differentiated data asset at the intersection of cardiovascular research, clinical insight and therapeutic development. This successful fundraise is a strong endorsement of both the company’s technology and its long‑term strategy. We’re pleased to have supported PlaqueTec on this important milestone and look forward to seeing the BioCarta platform continue to gain momentum.”

Katie Carter, Senior Associate, Burges Salmon

“This successful raise underlines the confidence our shareholders have in PlaqueTec’s data led approach to cardiovascular disease and the long term potential of the BioCarta platform. We’re grateful to Alex, Katie, Sophie and the Burges Salmon team for their outstanding support, sector insight and clear, commercial advice throughout the transaction.”

Mark Ebner, Head of Finance, at PlaqueTec

Related services

Related sectors

Related articles

01
10

See more from Burges Salmon

Want more Burges Salmon content? Add us as a preferred source on Google to your favourites list for content and news you can trust.

Update your preferred sources

Follow us on LinkedIn

Be sure to follow us on LinkedIn and stay up to date with all the latest from Burges Salmon.

Follow us